AHL
HCAT icon

Abel Hall LLC’s Health Catalyst HCAT Stock Holding History

Abel Hall LLC’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Buy
+10,557
New +$15.2K ﹤0.01% 942

Other funds holding HCAT

NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return
SRS
Strong Retirement Solutions Silverdale, Washington $167M AUM
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CI
Cigna Investments Bloomfield, Connecticut $773M AUM 44.02% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Abel Hall LLC's HCAT Position: Q2 2026 in Review

Abel Hall LLC opened a new position in Health Catalyst (HCAT) in Q2 2026: 10,557 shares worth $21K. The stake represents ﹤0.01% of the portfolio and ranks #942 among its holdings.

22 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • Abel Hall LLC held 10,557 shares of Health Catalyst worth $21K as of Q2 2026.
  • Health Catalyst was a new Abel Hall LLC position in Q2 2026.
  • Health Catalyst made up ﹤0.01% of Abel Hall LLC's portfolio in Q2 2026, its #942 holding.
  • 22 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.